papaverine has been researched along with spironolactone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Rosazza, JP; Smith, RV | 1 |
2 review(s) available for papaverine and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Microbial models for drug metabolism.
Topics: Acronine; Animals; Aporphines; Bacteria; Biotransformation; Cannabinoids; Chemical Phenomena; Chemistry; Cytochrome P-450 Enzyme System; Danazol; Daunorubicin; Ellipticines; Fungi; Indans; Mammals; Models, Biological; Oxidation-Reduction; Oxygenases; Papaverine; Pharmaceutical Preparations; Prostaglandins; Species Specificity; Spironolactone; Thiazoles; Yeasts | 1979 |
1 other study(ies) available for papaverine and spironolactone
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |